Earendil Labs vs Regeneron

Side-by-side comparison of AI visibility scores, market position, and capabilities

Regeneron leads in AI visibility (74 vs 53)
Earendil Labs logo

Earendil Labs

ChallengerBioTech

AI Drug Discovery

Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 2026; platform generates 40+ AI-designed protein therapeutics across multiple therapeutic areas.

AI VisibilityBeta
Overall Score
C53
Category Rank
#53 of 198
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
49
Perplexity
49
Gemini
55

About

Earendil Labs is a full-stack AI biologics company that uses a proprietary AI platform to design protein therapeutics at scale. The company secured $787 million in financing in March 2026, backed by Sanofi, the Pfizer-Hillhouse Biotech Fund, Dimension Capital, and DST Global — one of the largest AI drug discovery raises in the industry's history.

Full profile
Regeneron logo

Regeneron

LeaderLife Sciences & BioTech

Biopharmaceuticals

Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.

AI VisibilityBeta
Overall Score
B74
Category Rank
#9 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
74
Gemini
79

About

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.

Full profile

AI Visibility Head-to-Head

53
Overall Score
74
#53
Category Rank
#9
79
AI Consensus
73
stable
Trend
stable
49
ChatGPT
79
49
Perplexity
74
55
Gemini
79
55
Claude
68
48
Grok
75

Key Details

Category
AI Drug Discovery
Biopharmaceuticals
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Earendil Labs
AI Drug Discovery
Only Regeneron
Biopharmaceuticals

Integrations

Only Regeneron

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.